Published in Br J Cancer on March 24, 2009
Prognostic Factors in Prostate Cancer for Patients Treated by Watchful Waiting (TAPG) | NCT03912883
Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol (2011) 4.50
Prevention and early detection of prostate cancer. Lancet Oncol (2014) 2.94
Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS One (2013) 2.31
RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1. Lancet Oncol (2014) 1.88
SOX9 elevation in the prostate promotes proliferation and cooperates with PTEN loss to drive tumor formation. Cancer Res (2010) 1.64
The complexity of prostate cancer: genomic alterations and heterogeneity. Nat Rev Urol (2012) 1.59
Novel diagnostic biomarkers for prostate cancer. J Cancer (2010) 1.36
Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer. Br J Cancer (2013) 1.23
Phase II prospective randomized trial of a low-fat diet with fish oil supplementation in men undergoing radical prostatectomy. Cancer Prev Res (Phila) (2011) 1.23
Novel Biomarker Signature That May Predict Aggressive Disease in African American Men With Prostate Cancer. J Clin Oncol (2015) 1.14
Prognostic value of Ki-67 for prostate cancer death in a conservatively managed cohort. Br J Cancer (2013) 1.05
Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangement. Br J Cancer (2009) 1.04
Elevated level of Wnt5a protein in localized prostate cancer tissue is associated with better outcome. PLoS One (2011) 0.99
Ki-67 is an independent predictor of metastasis and cause-specific mortality for prostate cancer patients treated on Radiation Therapy Oncology Group (RTOG) 94-08. Int J Radiat Oncol Biol Phys (2013) 0.99
PRKC-ζ Expression Promotes the Aggressive Phenotype of Human Prostate Cancer Cells and Is a Novel Target for Therapeutic Intervention. Genes Cancer (2010) 0.98
Oral administration of naturally occurring chitosan-based nanoformulated green tea polyphenol EGCG effectively inhibits prostate cancer cell growth in a xenograft model. Carcinogenesis (2013) 0.95
Mir143 expression inversely correlates with nuclear ERK5 immunoreactivity in clinical prostate cancer. Br J Cancer (2013) 0.93
Imaging primary prostate cancer with 11C-Choline PET/CT: relation to tumour stage, Gleason score and biomarkers of biologic aggressiveness. Radiol Oncol (2012) 0.90
Brca2 and Trp53 deficiency cooperate in the progression of mouse prostate tumourigenesis. PLoS Genet (2010) 0.88
DNA methylation gene-based models indicating independent poor outcome in prostate cancer. BMC Cancer (2014) 0.87
Targeting therapy of hepatocellular carcinoma with doxorubicin prodrug PDOX increases anti-metastatic effect and reduces toxicity: a preclinical study. J Transl Med (2013) 0.86
An improved prognostic model for stage T1a and T1b prostate cancer by assessments of cancer extent. Mod Pathol (2010) 0.86
Ki-67 labeling index is a predictor of postoperative persistent disease and cancer growth and a prognostic indicator in papillary thyroid carcinoma. Eur Thyroid J (2013) 0.85
Cancer diagnostic classifiers based on quantitative DNA methylation. Expert Rev Mol Diagn (2014) 0.85
The role of treatment modality on the utility of predictive tissue biomarkers in clinical prostate cancer: a systematic review. J Cancer Res Clin Oncol (2012) 0.84
Quantifying the ki-67 heterogeneity profile in prostate cancer. Prostate Cancer (2013) 0.81
Prostate Cancer Genetics: Variation by Race, Ethnicity, and Geography. Semin Radiat Oncol (2016) 0.79
The proliferation marker Ki67, but not neuroendocrine expression, is an independent factor in the prediction of prognosis of primary prostate cancer patients. Radiol Oncol (2016) 0.79
Focal amplification of the androgen receptor gene in hormone-naive human prostate cancer. Br J Cancer (2014) 0.78
Novel approaches for the identification of biomarkers of aggressive prostate cancer. Genome Med (2013) 0.78
Immunohistochemical profile of ductal adenocarcinoma of the prostate. Virchows Arch (2014) 0.78
Immunohistochemical expression of minichromosome maintenance complex protein 2 predicts biochemical recurrence in prostate cancer: a tissue microarray and digital imaging analysis-based study of 428 cases. Hum Pathol (2012) 0.77
Ki67-BCL2 index in prognosis of malignant peritoneal mesothelioma. Am J Cancer Res (2013) 0.77
Evaluation of an epithelial plasticity biomarker panel in men with localized prostate cancer. Prostate Cancer Prostatic Dis (2015) 0.77
4-Methoxydalbergione suppresses growth and induces apoptosis in human osteosarcoma cells in vitro and in vivo xenograft model through down-regulation of the JAK2/STAT3 pathway. Oncotarget (2016) 0.76
Prognostic value of Ki67 in localized prostate carcinoma: a multi-institutional study of >1000 prostatectomies. Prostate Cancer Prostatic Dis (2016) 0.76
Comparison of digital image analysis and visual scoring of KI-67 in prostate cancer prognosis after prostatectomy. Diagn Pathol (2015) 0.76
Emphasizing the role of Wnt5a protein expression to predict favorable outcome after radical prostatectomy in patients with low-grade prostate cancer. Cancer Med (2012) 0.76
KI67 and DLX2 predict increased risk of metastasis formation in prostate cancer-a targeted molecular approach. Br J Cancer (2016) 0.75
Retracted Ability of PITX2 methylation to predict survival in patients with prostate cancer. Onco Targets Ther (2015) 0.75
Prognostic correlation of cell cycle progression score and Ki-67 as a predictor of aggressiveness, biochemical failure, and mortality in men with high-risk prostate cancer treated with external beam radiation therapy. Rep Pract Oncol Radiother (2017) 0.75
20-year outcomes following conservative management of clinically localized prostate cancer. JAMA (2005) 12.25
Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer (1983) 11.19
Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene (2007) 4.81
Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol (1991) 3.82
Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent. Cancer (2008) 3.06
Long-term outcome among men with conservatively treated localised prostate cancer. Br J Cancer (2006) 2.76
Complex patterns of ETS gene alteration arise during cancer development in the human prostate. Oncogene (2007) 2.68
Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02. J Clin Oncol (2004) 1.72
A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival. Br J Cancer (2006) 1.65
Local progression among men with conservatively treated localized prostate cancer: results from the Transatlantic Prostate Group. Eur Urol (2007) 1.60
Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. J Urol (1996) 1.29
Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: an analysis of patients in radiation therapy oncology group protocol 86-10. Clin Cancer Res (2004) 1.28
Prostate cancer incidence and mortality rates and trends in the United States and Canada. Public Health Rep (2004) 1.27
Androgen receptor, Ki67, and p53 expression in radical prostatectomy specimens predict treatment failure in Japanese population. Urology (2005) 1.08
Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy. Eur Urol (1999) 1.08
Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapy. Clin Cancer Res (2002) 1.07
Ki-67 expression in early prostate cancer and associated pathological lesions. J Clin Pathol (1996) 1.06
Radical prostatectomy: pathology findings in 1001 cases compared with other major series and over time. BJU Int (2005) 0.97
Evaluation of Ki-67 monoclonal antibody as prognostic indicator for prostatic carcinoma. Br J Urol (1993) 0.97
Apoptosis, mitosis, p53, bcl(2), Ki-67 and clinical outcome in prostate carcinoma treated by androgen ablation. Urol Int (1999) 0.92
Radical radiotherapy for prostate cancer. Cancer Treat Rev (2003) 0.87
Application of the monoclonal antibody Ki-67 on prostate biopsies to assess the fraction of human prostatic carcinoma. J Urol (1991) 0.84
[p53 and Ki67 expression in specimens of radical prostatectomy. Relationship with clinico-pathologic data and survival]. Actas Urol Esp (2000) 0.82
[The usefulness of Ki67 expression in the biopsy specimens, to predict the biochemical progresion of the prostate cancer after radical prostatectomy]. Actas Urol Esp (2004) 0.81
Biological aggressiveness of prostate cancer in the Finnish screening trial. Int J Cancer (2009) 0.81
[Use of the monoclonal antibody KI-67 in the study of the proliferative activity of urologic tumors. Preliminary data]. J Urol (Paris) (1987) 0.80
Multiclass cancer diagnosis using tumor gene expression signatures. Proc Natl Acad Sci U S A (2001) 19.30
The increasing disparity in mortality between socioeconomic groups in the United States, 1960 and 1986. N Engl J Med (1993) 16.94
A Wilcoxon-type test for trend. Stat Med (1985) 13.22
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet (2005) 11.05
Prevention of colorectal cancer by once-only sigmoidoscopy. Lancet (1993) 7.46
Scleritis-associated uveitis. Ophthalmology (1997) 7.34
Serious complications of topical mitomycin-C after pterygium surgery. Ophthalmology (1992) 6.62
Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature (1999) 6.50
The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int (2007) 6.44
MAD2 haplo-insufficiency causes premature anaphase and chromosome instability in mammalian cells. Nature (2001) 6.36
Risk of new vertebral fracture in the year following a fracture. JAMA (2001) 6.17
First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet (2002) 6.02
Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer (2002) 5.83
Epidemiology of fractures in England and Wales. Bone (2001) 5.76
Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. J Clin Microbiol (1997) 5.64
European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int (2008) 5.27
Induction of apoptosis in mature T cells by tumour necrosis factor. Nature (1995) 5.26
Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer. The National Co-ordinating Network for Cervical Screening Working Group. Br J Cancer (1996) 5.24
Long-term risk of colorectal cancer after excision of rectosigmoid adenomas. N Engl J Med (1992) 5.18
Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomised trial. Lancet (2002) 5.04
Perspective. How many women have osteoporosis? J Bone Miner Res (1992) 4.99
Maternal vitamin D status during pregnancy and childhood bone mass at age 9 years: a longitudinal study. Lancet (2006) 4.95
European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int (2012) 4.88
Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene (2007) 4.81
Radiographic patterns of osteoarthritis of the knee joint in the community: the importance of the patellofemoral joint. Ann Rheum Dis (1992) 4.79
Use of oral corticosteroids and risk of fractures. J Bone Miner Res (2000) 4.75
Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol (2000) 4.70
Progressive potential of mild cervical atypia: prospective cytological, colposcopic, and virological study. Lancet (1986) 4.55
EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis (2000) 4.37
Benefit of cervical screening at different ages: evidence from the UK audit of screening histories. Br J Cancer (2003) 4.14
An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors. Oncogene (2009) 4.10
Bone density screening for osteoporosis. Lancet (1990) 3.87
Defining osteoarthritis of the hip for epidemiologic studies. Am J Epidemiol (1990) 3.77
Excess mortality following hip fracture: a systematic epidemiological review. Osteoporos Int (2009) 3.74
The grading of rectal cancer: historical perspectives and a multivariate analysis of 447 cases. Histopathology (1986) 3.70
Cohort profile: the Hertfordshire cohort study. Int J Epidemiol (2005) 3.62
A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int (2012) 3.62
Bone densitometry in clinical practice. BMJ (1995) 3.48
The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int (2002) 3.45
Complete genomic sequence and analysis of the prion protein gene region from three mammalian species. Genome Res (1998) 3.44
Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int (2010) 3.36
The prevalence of vertebral deformity in european men and women: the European Vertebral Osteoporosis Study. J Bone Miner Res (1996) 3.25
Determinants of disability in osteoarthritis of the knee. Ann Rheum Dis (1993) 3.16
Fluoride in drinking water and risk of hip fracture in the UK: a case-control study. Lancet (2000) 3.16
Incidence of vertebral fracture in europe: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res (2002) 3.16
Knee pain and disability in the community. Br J Rheumatol (1992) 3.15
Mild cervical dyskaryosis: safety of cytological surveillance. Lancet (1992) 3.09
Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene (2006) 3.09
Referral patterns of uveitis in a tertiary eye care center. Arch Ophthalmol (1996) 3.04
Pectin esterification is spatially regulated both within cell walls and between developing tissues of root apices. Planta (1990) 3.03
A postoperative prognostic nomogram for renal cell carcinoma. J Urol (2001) 3.01
GP job satisfaction in 1987, 1990 and 1998: lessons for the future? Fam Pract (2000) 2.99
Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum (2003) 2.94
Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol (2006) 2.94
Maternal vitamin D status during pregnancy and child outcomes. Eur J Clin Nutr (2007) 2.94
Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis. Osteoporos Int (2012) 2.81
Effect of annual intramuscular vitamin D on fracture risk in elderly men and women--a population-based, randomized, double-blind, placebo-controlled trial. Rheumatology (Oxford) (2007) 2.81
Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease. Osteoporos Int (1997) 2.80
Long-term outcome among men with conservatively treated localised prostate cancer. Br J Cancer (2006) 2.76
Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas (2009) 2.74
Back pain in Britain: comparison of two prevalence surveys at an interval of 10 years. BMJ (2000) 2.73
Genetic alterations in bladder cancer. Lancet (1993) 2.73
Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis. Osteoporos Int (1999) 2.70
A global representation of vitamin D status in healthy populations. Arch Osteoporos (2012) 2.69
Osteoarthritis of the hip: an occupational disease in farmers. BMJ (1992) 2.69
Complex patterns of ETS gene alteration arise during cancer development in the human prostate. Oncogene (2007) 2.68
The prognostic value of kidney transplant center report cards. Am J Transplant (2013) 2.64
Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol (2002) 2.61
Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J Bone Miner Res (2000) 2.55
Determining the area under the ROC curve for a binary diagnostic test. Med Decis Making (2001) 2.54
Occupational physical activities and osteoarthritis of the knee. Arthritis Rheum (2000) 2.54
Manual handling activities and risk of low back pain in nurses. Occup Environ Med (1995) 2.48
Impact of nutrition on muscle mass, strength, and performance in older adults. Osteoporos Int (2012) 2.48
Use of statins and risk of fractures. JAMA (2001) 2.47
Prospective cohort study of predictors of incident low back pain in nurses. BMJ (1997) 2.46
Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome. Proc Natl Acad Sci U S A (1998) 2.46
Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol (2012) 2.45
Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br J Cancer (2010) 2.45